Chandler Park, MD, MSc, FACP

Drs Park and Marshall traced the evolution of pancreatic cancer management over the past decades, culminating in the emergence of RAS-directed therapy.

Drs Park and Grivas discuss key bladder cancer data presented at the 2026 ESMO Congress, highlighting the rapidly expanding treatment landscape.

Edgardo S. Santos Castillero, MD, FACP, FASCO, of The Oncology Institute, and Balazs Halmos, MD, MS, of Montefiore Health System and Albert Einstein College of Medicine, sit down with Chandler H. Park, MD, MSc, FACP, of Norton Cancer Institute, to discuss the latest abstracts in small cell and non–small cell lung cancer presented during the 2026 ESMO Congress.

Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute and Harvard Medical School, and Andrew W. Hahn, MD, of The University of Texas MD Anderson Cancer Center, sit down with Chandler H. Park, MD, MSc, FACP, of Norton Cancer Institute, to discuss the latest abstracts in breast and prostate cancers presented during the 2026 ESMO Congress.

Alexandra Drakaki, MD, PhD, of the UCLA Health Institute of Urologic Oncology, and Guru P. Sonpavde, MD, of AdventHealth, sit down with Chandler H. Park, MD, MSc, FACP, of Norton Cancer Institute, to discuss the latest abstracts in bladder cancer presented during the 2026 ESMO Congress.

Drs Park and Abraham discuss practice-changing advances in breast cancer, treatment de-escalation, ADCs, and the growing role of AI in oncology.

Drs Park and Kasi discuss the rise of neoadjuvant immunotherapy in CRC management, framing how this shift fits into the context of larger paradigm changes.

Drs Park and Brody highlight the rapidly evolving treatment landscape for B-cell lymphomas, noting advances across frontline and relapsed settings.

Drs Park and Brody discuss the evolving frontline and relapsed treatment landscape in Hodgkin lymphoma.

Drs Park and Liu discuss precision oncology, bispecific antibodies, and next-generation targeted therapies in NSCLC.

Drs Park and Baljevic discussed the evolution of myeloma management, including the integration of quadruplet therapies and bispecific antibodies.

Drs Park and Iyengar discuss the evolving treatment paradigm for TNBC, the integration of metabolic health strategies, and the clinical emergence of ADCs.

Drs Park and Beckermann discuss kidney cancer highlights from the 2026 Genitourinary Cancers Symposium.

Amandeep Salhotra, MD, and Robert Negrin, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in graft-vs-host disease presented during the 2025 ASH Annual Meeting & Exposition.

Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.

Gerhard Hildebrandt, MD, FACP, and Muhamed Baljevic, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in acute leukemia and multiple myeloma presented during the 2025 ASH Annual Meeting & Exposition.

Neeraj Agarwal, MD, FASCO, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in prostate cancer presented during the 2025 ESMO Congress.

David H. Aggen, MD, PhD, Petros Grivas, MD, PhD, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in bladder cancer presented during the 2025 ESMO Congress.

Brian I. Rini, MD, FASCO, and Katy Beckermann, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in renal cell carcinoma presented during the 2025 ESMO Congress.

Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Narjust Florez, MD, and Joshua K. Sabari, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Drs Park and Malla discuss therapeutic options for patients with metastatic colorectal cancer, particularly in the third-line setting and beyond.

Chandler Park, MD and Midhun Malla, MD discuss treatment personalization in mCRC, with a focus on BRAF V600E–mutant tumors and HER2-altered disease.

MedNews Week host Yan Leyfman, MD, speaks with 2 key opinion leaders at ASCO 2025 about the top data highlights of the day.

MedNews Week hosts speak with 8 key opinion leaders at ASCO 2025 about the top data highlights of the day.

MedNews Week hosts speak with 5 key opinion leaders at ASCO 2025 about the top data highlights of the day.

Park and Malla discuss evolving approaches to colorectal cancer (CRC) management, with a focus on ctDNA, adjuvant therapy decision-making, and molecular profiling in metastatic disease.

Drs Park and Hanona discuss the ways that public health content creation offers practical advice about a variety of topics but may also spark debate.

In this episode, Drs Park and Hanona give advice to up-and-coming oncology content creators.